Altimmune, Inc. — Director's Dealing 2010

Nov 6, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2010-11-03

Reporting Person: RICHMAN ERIC I (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-11-03	Common Stock	C	7306	$2.5417	Acquired	77879	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-11-03	10% Convertible Note	$2.5417	C		Disposed	2011-07-28	Common Stock (7306)	Direct
2010-11-03	Option to purchase	$3.34	A	125000	Acquired	2020-11-03	Common Stock (125000)	Direct

Footnotes

F1: The 10% Convertible Note (the "Note") including accrued interest thereon, was convertible into the Issuer's Common Stock at a
price of $2.541667 per share.

F2: Immediately.

F3: This Note together with a Warrant was received pursuant to a Note and Warrant Purchase Agreement dated as of July 24, 2009,
as amended on July 26, 2009 and July 28, 2009, by and among the Issuer and certain noteholders, all as more specifically
reported on Form 4 filed with the Securities & Exchange Commission on July 30, 2009.

F4: The option vests 25% per year beginning on the first anniversary on the date of grant.

F5: The closing price of the Issuer's common stock on the NYSE Amex on November 3, 2010, the date the option was granted, was
$3.34.